Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb
|
12/12/24
|
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb
|
PDF
|
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
|
12/05/24
|
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
|
PDF
|
Bausch Health Appoints New Chief Medical Officer and Head of R&D
|
12/02/24
|
Bausch Health Appoints New Chief Medical Officer and Head of R&D
|
PDF
|
Bausch Health and Salix to present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a new investigational product designed to address serious complications of cirrhosis
|
11/18/24
|
Bausch Health and Salix to present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a new investigational product designed to address serious complications of cirrhosis
|
PDF
|
Bausch Health Announces Third Quarter 2024 Results
|
10/30/24
|
Bausch Health Announces Third Quarter 2024 Results
|
PDF
|
ACG Presidential Plenary to Highlight Analysis of Xifaxan® (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
|
10/28/24
|
ACG Presidential Plenary to Highlight Analysis of Xifaxan® (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
|
PDF
|
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
|
10/09/24
|
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
|
PDF
|
Bausch Health and Salix survey highlights urgent need for improved understanding of liver disease across healthcare provider disciplines as prevalence of cirrhosis rises
|
10/08/24
|
Bausch Health and Salix survey highlights urgent need for improved understanding of liver disease across healthcare provider disciplines as prevalence of cirrhosis rises
|
PDF
|
Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
|
08/13/24
|
Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
|
PDF
|
Bausch Health Announces Second Quarter 2024 Results
|
08/01/24
|
Bausch Health Announces Second Quarter 2024 Results
|
PDF
|
Bausch Health Responds to Market Rumors
|
07/24/24
|
Bausch Health Responds to Market Rumors
|
PDF
|
Bausch Health Welcomes Two New Members to the Executive Leadership Team
|
07/19/24
|
Bausch Health Welcomes Two New Members to the Executive Leadership Team
|
PDF
|
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
|
07/11/24
|
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
|
PDF
|
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
|
06/20/24
|
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
|
PDF
|
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
|
06/14/24
|
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
|
PDF
|
Bausch Health, Canada Inc. announces additional public drug plan listings for PrUCERIS® (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults
|
05/23/24
|
Bausch Health, Canada Inc. announces additional public drug plan listings for PrUCERIS® (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults
|
PDF
|
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
|
05/17/24
|
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
|
PDF
|
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
|
05/15/24
|
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
|
PDF
|
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
|
05/14/24
|
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
|
PDF
|
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan® (rifaximin)
|
05/09/24
|
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan® (rifaximin)
|
PDF
|
Bausch Health Announces First Quarter 2024 Results
|
05/02/24
|
Bausch Health Announces First Quarter 2024 Results
|
PDF
|
Bausch Health to Announce First-Quarter 2024 Results on May 2
|
04/11/24
|
Bausch Health to Announce First-Quarter 2024 Results on May 2
|
PDF
|
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
|
04/11/24
|
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
|
PDF
|
Acne vulgaris treatment PrARAZLO™ (tazarotene lotion, 0.045%) now available to patients through British Columbia PharmaCare public drug plan
|
04/11/24
|
Acne vulgaris treatment PrARAZLO™ (tazarotene lotion, 0.045%) now available to patients through British Columbia PharmaCare public drug plan
|
PDF
|
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
|
04/05/24
|
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
|
PDF
|
Bausch Health, Canada Inc. announces first public drug plan listings for PrUCERIS® (budesonide) aerosol foam to help address the unmet need for the treatment of mild to moderate distal ulcerative colitis in adults
|
04/03/24
|
Bausch Health, Canada Inc. announces first public drug plan listings for PrUCERIS® (budesonide) aerosol foam to help address the unmet need for the treatment of mild to moderate distal ulcerative colitis in adults
|
PDF
|
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
|
04/02/24
|
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
|
PDF
|
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR® (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
|
03/06/24
|
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR® (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
|
PDF
|
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How to Prepare for the Procedure
|
03/05/24
|
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How to Prepare for the Procedure
|
PDF
|
Bausch Health Companies to Present at Cowen Annual Health Care Conference
|
03/01/24
|
Bausch Health Companies to Present at Cowen Annual Health Care Conference
|
PDF
|
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
|
02/22/24
|
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
|
PDF
|
Salix Announces 2024 Gastrointestinal Health Scholars Program
|
02/12/24
|
Salix Announces 2024 Gastrointestinal Health Scholars Program
|
PDF
|
Bausch Health Announces Board Refreshment
|
02/01/24
|
Bausch Health Announces Board Refreshment
|
PDF
|
Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22
|
02/01/24
|
Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22
|
PDF
|
CABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
|
01/30/24
|
CABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
|
PDF
|
Solta Medical’s Thermage® FLX and TR-4 Return Pad Receive Registration Certifications in China
|
01/18/24
|
Solta Medical’s Thermage® FLX and TR-4 Return Pad Receive Registration Certifications in China
|
PDF
|
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
|
01/08/24
|
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
|
PDF
|
Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis
|
12/21/23
|
Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis
|
PDF
|
DUOBRII™ lotion to treat moderate to severe plaque psoriasis now available through Quebec’s public drug plan
|
12/18/23
|
DUOBRII™ lotion to treat moderate to severe plaque psoriasis now available through Quebec’s public drug plan
|
PDF
|
Salix In Collaboration With The U.S. Pain Foundation And The International Foundation For Gastrointestinal Disorders Establish The Inaugural Opioid- Induced Constipation (Oic) Awareness Day
|
12/05/23
|
Salix In Collaboration With The U.S. Pain Foundation And The International Foundation For Gastrointestinal Disorders Establish The Inaugural Opioid- Induced Constipation (Oic) Awareness Day
|
PDF
|
The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
|
11/10/23
|
The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
|
PDF
|
As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)
|
11/08/23
|
As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)
|
PDF
|
Bausch Health Announces Third-Quarter 2023 Results
|
11/02/23
|
Bausch Health Announces Third-Quarter 2023 Results
|
PDF
|
U.S. District Court Dismisses Norwich’s Lawsuit Against the FDA
|
11/01/23
|
U.S. District Court Dismisses Norwich’s Lawsuit Against the FDA
|
PDF
|
Bausch Health Unveils "Looking Forward" – A New DTC Television Campaign for Seasonal Affective Disorder (SAD)
|
10/25/23
|
Bausch Health Unveils "Looking Forward" – A New DTC Television Campaign for Seasonal Affective Disorder (SAD)
|
PDF
|
FDA Approves CabtreoTM (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel For The Treatment Of Acne Vulgaris In Patients Twelve Years Of Age And Older
|
10/20/23
|
FDA Approves CabtreoTM (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel For The Treatment Of Acne Vulgaris In Patients Twelve Years Of Age And Older
|
PDF
|
New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk for OHE Recurrence
|
10/17/23
|
New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk for OHE Recurrence
|
PDF
|
Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2
|
10/12/23
|
Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2
|
PDF
|
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase In Chronic Liver Disease And Cirrhosis-related Deaths Marking These As Ninth Leading Cause Of Death In U.S.
|
10/10/23
|
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase In Chronic Liver Disease And Cirrhosis-related Deaths Marking These As Ninth Leading Cause Of Death In U.S.
|
PDF
|
Salix Pharmaceuticals partners with Bellamy Young
|
10/04/23
|
Salix Pharmaceuticals partners with Bellamy Young
|
PDF
|
Bausch Health’s Bausch + Lomb Announces Completion of the Acquisition of XIIDRA®
|
09/29/23
|
Bausch Health’s Bausch + Lomb Announces Completion of the Acquisition of XIIDRA®
|
PDF
|
League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease
|
09/21/23
|
League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease
|
PDF
|
Bausch Health announces CFO Transition Plan
|
09/18/23
|
Bausch Health announces CFO Transition Plan
|
PDF
|
New Bausch Health treatment PrUCERIS® (budesonide) aerosol foam now available across Canada to treat mild to moderate distal ulcerative colitis in adults
|
09/12/23
|
New Bausch Health treatment PrUCERIS® (budesonide) aerosol foam now available across Canada to treat mild to moderate distal ulcerative colitis in adults
|
PDF
|
Bausch Health’s Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®
|
09/11/23
|
Bausch Health’s Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®
|
PDF
|
Bausch Health’s Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®
|
09/06/23
|
Bausch Health’s Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®
|
PDF
|
Bausch Health Announces Second-Quarter 2023 Results, other key updates from the Quarter, and raises Full-Year 2023 Revenue Outlook
|
08/03/23
|
Bausch Health Announces Second-Quarter 2023 Results, other key updates from the Quarter, and raises Full-Year 2023 Revenue Outlook
|
PDF
|
Ortho Dermatologics Announces 2023 Aspire Higher Scholarship Recipients
|
07/27/23
|
Ortho Dermatologics Announces 2023 Aspire Higher Scholarship Recipients
|
PDF
|
Bausch Health to Announce Second-Quarter 2023 Results on Aug. 3
|
07/13/23
|
Bausch Health to Announce Second-Quarter 2023 Results on Aug. 3
|
PDF
|
Salix Announces 2023 Gastrointestinal Health Scholars Program Winners
|
07/11/23
|
Salix Announces 2023 Gastrointestinal Health Scholars Program Winners
|
PDF
|
OraPharma to Participate in the First-Ever Research and Technology Pavilion Sponsored by Pacific Dental Services® at the American Dental Hygienists’ Association (ADHA®) Annual Conference
|
07/07/23
|
OraPharma to Participate in the First-Ever Research and Technology Pavilion Sponsored by Pacific Dental Services® at the American Dental Hygienists’ Association (ADHA®) Annual Conference
|
PDF
|
Bausch Health Enters Into $600 Million Financing Facility With KKR
|
07/07/23
|
Bausch Health Enters Into $600 Million Financing Facility With KKR
|
PDF
|
Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA®
|
06/30/23
|
Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA®
|
PDF
|
Salix to Present Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2023
|
06/19/23
|
Salix to Present Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2023
|
PDF
|
Bausch Health Responds to Norwich’s ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration
|
06/06/23
|
Bausch Health Responds to Norwich’s ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration
|
PDF
|
OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease
|
05/31/23
|
OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease
|
PDF
|
New Clinical Study Suggests the Use of OraPharma’s ARESTIN® (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis
|
05/18/23
|
New Clinical Study Suggests the Use of OraPharma’s ARESTIN® (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis
|
PDF
|
U.S. District Court Upholds Final Judgment for XIFAXAN® 550 mg That Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
|
05/17/23
|
U.S. District Court Upholds Final Judgment for XIFAXAN® 550 mg That Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
|
PDF
|
Bausch Health Announces 2023 Annual Meeting of Shareholder Results
|
05/17/23
|
Bausch Health Announces 2023 Annual Meeting of Shareholder Results
|
PDF
|
Bausch Health Observes Mental Health Awareness Month
|
05/10/23
|
Bausch Health Observes Mental Health Awareness Month
|
PDF
|
Salix Pharmaceuticals To Deliver Podium Presentation At Digestive Disease Week® 2023
|
05/08/23
|
Salix Pharmaceuticals To Deliver Podium Presentation At Digestive Disease Week® 2023
|
PDF
|
Bausch Health Announces First-Quarter 2023 Results
|
05/04/23
|
Bausch Health Announces First-Quarter 2023 Results
|
PDF
|
Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel
|
05/01/23
|
Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel
|
PDF
|
Salix Partners with the Colorectal Cancer Alliance on Community Screening Program
|
04/24/23
|
Salix Partners with the Colorectal Cancer Alliance on Community Screening Program
|
PDF
|
Bausch Health to Announce First-Quarter 2023 Results on May 4
|
04/13/23
|
Bausch Health to Announce First-Quarter 2023 Results on May 4
|
PDF
|
More than half of IBS patients surveyed report waiting more than one year before discussing IBS symptoms with their healthcare provider
|
04/04/23
|
More than half of IBS patients surveyed report waiting more than one year before discussing IBS symptoms with their healthcare provider
|
PDF
|
Bausch Health Announces Changes to its Board of Directors
|
03/01/23
|
Bausch Health Announces Changes to its Board of Directors
|
PDF
|
Bausch Health Announces Fourth-Quarter and Full-Year 2022 Results
|
02/23/23
|
Bausch Health Announces Fourth-Quarter and Full-Year 2022 Results
|
PDF
|
Salix Announces 2023 Gastrointestinal Health Scholars Program
|
02/13/23
|
Salix Announces 2023 Gastrointestinal Health Scholars Program
|
PDF
|
Bausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23
|
02/01/23
|
Bausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23
|
PDF
|
First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans
|
12/22/22
|
First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans
|
PDF
|
Bausch Health Wins DUOBRII® and BRYHALI® Patent Infringement Case
|
12/02/22
|
Bausch Health Wins DUOBRII® and BRYHALI® Patent Infringement Case
|
PDF
|
Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider
|
12/01/22
|
Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider
|
PDF
|
Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Covenants
|
11/29/22
|
Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Covenants
|
PDF
|
Salix Will Present Rifaximin Data at AASLD's The Liver Meeting(R) 2022
|
11/04/22
|
Salix Will Present Rifaximin Data at AASLD's The Liver Meeting(R) 2022
|
PDF
|
Bausch Health Companies Inc. Announces Third-Quarter 2022 Results
|
11/03/22
|
Bausch Health Companies Inc. Announces Third-Quarter 2022 Results
|
PDF
|
Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference
|
11/01/22
|
Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference
|
PDF
|
Ortho Dermatologics Announces U.S. Launch of the Podiatry Board Review Challenge
|
10/31/22
|
Ortho Dermatologics Announces U.S. Launch of the Podiatry Board Review Challenge
|
PDF
|
Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting
|
10/24/22
|
Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting
|
PDF
|
Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference
|
10/20/22
|
Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference
|
PDF
|
Bausch Health to Announce Third Quarter 2022 Results on Nov. 3
|
10/13/22
|
Bausch Health to Announce Third Quarter 2022 Results on Nov. 3
|
PDF
|
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Underscoring Challenges in Caring for Growing Chronic Liver Disease and Cirrhotic Patient Population
|
10/12/22
|
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Underscoring Challenges in Caring for Growing Chronic Liver Disease and Cirrhotic Patient Population
|
PDF
|
Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022
|
10/05/22
|
Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022
|
PDF
|
Salix Pharmaceuticals Applauds Implementation of K76.82 – a New ICD-10 Code for Hepatic Encephalopathy
|
10/03/22
|
Salix Pharmaceuticals Applauds Implementation of K76.82 – a New ICD-10 Code for Hepatic Encephalopathy
|
PDF
|
Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations
|
09/28/22
|
Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations
|
PDF
|
Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations
|
09/14/22
|
Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations
|
PDF
|
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin
|
09/09/22
|
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin
|
PDF
|
Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations
|
09/08/22
|
Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations
|
PDF
|
Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes
|
08/30/22
|
Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes
|
PDF
|
Bausch Health Continuing Process Toward Separating Bausch + Lomb
|
08/22/22
|
Bausch Health Continuing Process Toward Separating Bausch + Lomb
|
PDF
|
Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit
|
08/10/22
|
Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit
|
PDF
|
Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)
|
08/10/22
|
Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)
|
PDF
|
Bausch Health Announces Second-Quarter 2022 Results
|
08/09/22
|
Bausch Health Announces Second-Quarter 2022 Results
|
PDF
|
Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation
|
07/28/22
|
Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation
|
PDF
|
Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9
|
07/27/22
|
Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9
|
PDF
|
Salix Announces 2022 Gastrointestinal Health Scholars Program Winners
|
07/13/22
|
Salix Announces 2022 Gastrointestinal Health Scholars Program Winners
|
PDF
|
Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors
|
06/23/22
|
Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors
|
PDF
|
Bausch Health Issues Form 8-K for 2022 Annual Meeting of Shareholders Presentation
|
06/21/22
|
Bausch Health Issues Form 8-K for 2022 Annual Meeting of Shareholders Presentation
|
PDF
|
Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2022
|
06/20/22
|
Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2022
|
PDF
|
Bausch Health Provides Update on Solta Medical
|
06/16/22
|
Bausch Health Provides Update on Solta Medical
|
PDF
|
Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022
|
05/18/22
|
Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022
|
PDF
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
05/11/22
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions
|
05/10/22
|
Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions
|
PDF
|
Bausch Health Companies Inc. Announces First-Quarter 2022 Results
|
05/10/22
|
Bausch Health Companies Inc. Announces First-Quarter 2022 Results
|
PDF
|
Bausch Health Announces Thomas J. Appio As Chief Executive Officer
|
05/06/22
|
Bausch Health Announces Thomas J. Appio As Chief Executive Officer
|
PDF
|
Bausch + Lomb Corporation Announces Pricing of IPO
|
05/05/22
|
Bausch + Lomb Corporation Announces Pricing of IPO
|
PDF
|
Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting
|
05/03/22
|
Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting
|
PDF
|
Bausch Health Companies Inc. Will Release First-Quarter 2022 Financial Results On May 10
|
04/29/22
|
Bausch Health Companies Inc. Will Release First-Quarter 2022 Financial Results On May 10
|
PDF
|
Bausch + Lomb Corporation Announces Launch of IPO and Roadshow
|
04/28/22
|
Bausch + Lomb Corporation Announces Launch of IPO and Roadshow
|
PDF
|
Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation
|
04/28/22
|
Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation
|
PDF
|
Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting
|
04/28/22
|
Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting
|
PDF
|
Ortho Dermatologics Will Present Data at the 2022 Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference
|
04/27/22
|
Ortho Dermatologics Will Present Data at the 2022 Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference
|
PDF
|
Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting
|
04/25/22
|
Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting
|
PDF
|
Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
|
04/21/22
|
Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
|
PDF
|
Bausch + Lomb Corporation Seeking to Enter Into New Credit Facilities to Facilitate Previously Announced Separation from Bausch Health
|
04/20/22
|
Bausch + Lomb Corporation Seeking to Enter Into New Credit Facilities to Facilitate Previously Announced Separation from Bausch Health
|
PDF
|
Bausch + Lomb Will Present New Scientific Data During the American Society of Cataract and Refractive Surgery Annual Meeting
|
04/18/22
|
Bausch + Lomb Will Present New Scientific Data During the American Society of Cataract and Refractive Surgery Annual Meeting
|
PDF
|
HALF OF IBS PATIENTS SURVEYED REPORT IBS SYMPTOMS MORE CHALLENGING TO MANAGE IN THE PAST YEAR
|
04/04/22
|
HALF OF IBS PATIENTS SURVEYED REPORT IBS SYMPTOMS MORE CHALLENGING TO MANAGE IN THE PAST YEAR
|
PDF
|
Bausch Health Will Reduce Debt By $200 Million
|
03/29/22
|
Bausch Health Will Reduce Debt By $200 Million
|
PDF
|
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
|
03/28/22
|
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
|
PDF
|
New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix's RELISTOR® Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency Department Is Published in Advances In Therapy
|
03/24/22
|
New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix's RELISTOR® Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency Department Is Published in Advances In Therapy
|
PDF
|
Gary Gemignani Will Join Solta Medical Corporation As Chief Financial Officer
|
03/22/22
|
Gary Gemignani Will Join Solta Medical Corporation As Chief Financial Officer
|
PDF
|
Ortho Dermatologics Will Present New Data at the 2022 American Academy of Dermatology Annual Meeting
|
03/22/22
|
Ortho Dermatologics Will Present New Data at the 2022 American Academy of Dermatology Annual Meeting
|
PDF
|
Bausch Health Announces Participation in Upcoming Investor Conferences
|
03/03/22
|
Bausch Health Announces Participation in Upcoming Investor Conferences
|
PDF
|
Ortho Dermatologics Now Accepting Applications for 2022 Aspire Higher Scholarship Program
|
03/02/22
|
Ortho Dermatologics Now Accepting Applications for 2022 Aspire Higher Scholarship Program
|
PDF
|
Salix and Colon Cancer Coalition Join Forces for 'Faces of Blue' Story Series to Raise Awareness of Colorectal Cancer Screenings
|
03/01/22
|
Salix and Colon Cancer Coalition Join Forces for 'Faces of Blue' Story Series to Raise Awareness of Colorectal Cancer Screenings
|
PDF
|
Bausch Health Announces Participation At The J.P. Morgan Global High Yield & Leveraged Finance Conference
|
02/24/22
|
Bausch Health Announces Participation At The J.P. Morgan Global High Yield & Leveraged Finance Conference
|
PDF
|
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2021 Results And Provides 2022 Guidance
|
02/23/22
|
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2021 Results And Provides 2022 Guidance
|
PDF
|
OraPharma Launches OraFit™ Custom Clear Dental Aligner System
|
02/22/22
|
OraPharma Launches OraFit™ Custom Clear Dental Aligner System
|
PDF
|
Salix Announces 2022 Gastrointestinal Health Scholars Program
|
02/15/22
|
Salix Announces 2022 Gastrointestinal Health Scholars Program
|
PDF
|
Solta Medical Corporation Files Registration Statement for Proposed Initial Public Offering
|
02/08/22
|
Solta Medical Corporation Files Registration Statement for Proposed Initial Public Offering
|
PDF
|
Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2021 Financial Results on February 23
|
02/03/22
|
Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2021 Financial Results on February 23
|
PDF
|
BAUSCH + LOMB AND PREVENT BLINDNESS LAUNCH ANNUAL AMD AWARENESS MONTH CAMPAIGN TO EDUCATE PATIENTS
|
02/01/22
|
BAUSCH + LOMB AND PREVENT BLINDNESS LAUNCH ANNUAL AMD AWARENESS MONTH CAMPAIGN TO EDUCATE PATIENTS
|
PDF
|
Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes
|
01/27/22
|
Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes
|
PDF
|
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes
|
01/27/22
|
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes
|
PDF
|
Dr. Yehia Hashad Will Join Bausch + Lomb Corporation as Executive Vice President of Research & Development and Chief Medical Officer
|
01/20/22
|
Dr. Yehia Hashad Will Join Bausch + Lomb Corporation as Executive Vice President of Research & Development and Chief Medical Officer
|
PDF
|
Bausch Health Announces It Is Seeking To Refinance Its Existing Credit Agreement And Conditional Redemption Of Existing Notes - These Steps Will Enable Bausch + Lomb IPO And Facilitate Full Separation
|
01/18/22
|
Bausch Health Announces It Is Seeking To Refinance Its Existing Credit Agreement And Conditional Redemption Of Existing Notes - These Steps Will Enable Bausch + Lomb IPO And Facilitate Full Separation
|
PDF
|
Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering
|
01/13/22
|
Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering
|
PDF
|
Bausch Health Will Provide Business And Strategic Update At The 40th Annual J.P. Morgan Healthcare Conference
|
01/11/22
|
Bausch Health Will Provide Business And Strategic Update At The 40th Annual J.P. Morgan Healthcare Conference
|
PDF
|
Bausch Health to Participate at the 40th Annual J.P. Morgan Healthcare Conference
|
01/05/22
|
Bausch Health to Participate at the 40th Annual J.P. Morgan Healthcare Conference
|
PDF
|
New Survey from Bausch + Lomb and Glaucoma Research Foundation Reveals Emotional and Social Impact of Hyperemia on Glaucoma Patients
|
01/04/22
|
New Survey from Bausch + Lomb and Glaucoma Research Foundation Reveals Emotional and Social Impact of Hyperemia on Glaucoma Patients
|
PDF
|
Relistor® (Methylnaltrexone Bromide) Data is Published in the Journal of Emergency Medicine
|
12/22/21
|
Relistor® (Methylnaltrexone Bromide) Data is Published in the Journal of Emergency Medicine
|
PDF
|
APMA Grants Seal of Approval for JUBLIA® (efinaconazole) Topical Solution, 10%
|
12/06/21
|
APMA Grants Seal of Approval for JUBLIA® (efinaconazole) Topical Solution, 10%
|
PDF
|
Salix Brings Educational Resources on Constipation Into the Homes of Patients and Caregivers for Constipation Awareness Month
|
12/03/21
|
Salix Brings Educational Resources on Constipation Into the Homes of Patients and Caregivers for Constipation Awareness Month
|
PDF
|
Bausch + Lomb Reports More Than 41 Million Units Of Contact Lens, Eye And Lens Care Materials Recycled Through ONE By ONE And Biotrue® Eye Care Recycling Programs
|
11/15/21
|
Bausch + Lomb Reports More Than 41 Million Units Of Contact Lens, Eye And Lens Care Materials Recycled Through ONE By ONE And Biotrue® Eye Care Recycling Programs
|
PDF
|
Salix Will Share New Rifaximin Data At AASLD's The Liver Meeting™ 2021
|
11/11/21
|
Salix Will Share New Rifaximin Data At AASLD's The Liver Meeting™ 2021
|
PDF
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
11/04/21
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
Bausch Health Companies Inc. Announces Third-Quarter 2021 Results
|
11/02/21
|
Bausch Health Companies Inc. Announces Third-Quarter 2021 Results
|
PDF
|
Bausch + Lomb Will Present Scientific Data and Analyses During the American Academy of Ophthalmology and American Academy of Optometry Annual Meetings
|
11/01/21
|
Bausch + Lomb Will Present Scientific Data and Analyses During the American Academy of Ophthalmology and American Academy of Optometry Annual Meetings
|
PDF
|
Bausch + Lomb Launches Biotrue® Eye Care Recycling Program in Collaboration With TerraCycle in the United States
|
10/27/21
|
Bausch + Lomb Launches Biotrue® Eye Care Recycling Program in Collaboration With TerraCycle in the United States
|
PDF
|
New Report Reveals Barriers To Quality Care For Chronic Liver Disease Patients, A Cause Of Morbidity And Mortality Projected To Grow In The United States
|
10/25/21
|
New Report Reveals Barriers To Quality Care For Chronic Liver Disease Patients, A Cause Of Morbidity And Mortality Projected To Grow In The United States
|
PDF
|
Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific Meeting
|
10/25/21
|
Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific Meeting
|
PDF
|
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
|
10/25/21
|
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
|
PDF
|
Bausch Health Announces Tom Vadaketh Will Join Bausch Pharma* As Chief Financial Officer
|
10/21/21
|
Bausch Health Announces Tom Vadaketh Will Join Bausch Pharma* As Chief Financial Officer
|
PDF
|
Ortho Dermatologics To Present New Data At The 2021 Fall Clinical Dermatology Conference
|
10/19/21
|
Ortho Dermatologics To Present New Data At The 2021 Fall Clinical Dermatology Conference
|
PDF
|
Bausch Health Companies Inc. Will Release Third-Quarter 2021 Financial Results On November 2
|
10/06/21
|
Bausch Health Companies Inc. Will Release Third-Quarter 2021 Financial Results On November 2
|
PDF
|
Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction
|
09/30/21
|
Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction
|
PDF
|
Bausch Health Releases Annual Environmental, Social and Governance Report
|
09/29/21
|
Bausch Health Releases Annual Environmental, Social and Governance Report
|
PDF
|
Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021
|
09/02/21
|
Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021
|
PDF
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
09/01/21
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
Bausch Health Companies Inc. Announces Second-Quarter 2021 Results
|
08/03/21
|
Bausch Health Companies Inc. Announces Second-Quarter 2021 Results
|
PDF
|
Bausch Health Announces Plans To Pursue An Initial Public Offering Of Solta Medical
|
08/03/21
|
Bausch Health Announces Plans To Pursue An Initial Public Offering Of Solta Medical
|
PDF
|
Bausch Health To Reduce Debt By $350 Million
|
08/03/21
|
Bausch Health To Reduce Debt By $350 Million
|
PDF
|
Bausch Health Completes Sale Of Amoun Pharmaceutical To ADQ
|
08/02/21
|
Bausch Health Completes Sale Of Amoun Pharmaceutical To ADQ
|
PDF
|
Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Recipients
|
07/29/21
|
Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Recipients
|
PDF
|
Salix Announces 2021 Gastrointestinal Health Scholars Program Winners
|
07/22/21
|
Salix Announces 2021 Gastrointestinal Health Scholars Program Winners
|
PDF
|
Bausch + Lomb Will Present 14 Scientific Posters Featuring New Analyses Involving Its Surgical Technologies At The 2021 Annual Meeting Of The American Society Of Cataract And Refractive Surgery
|
07/19/21
|
Bausch + Lomb Will Present 14 Scientific Posters Featuring New Analyses Involving Its Surgical Technologies At The 2021 Annual Meeting Of The American Society Of Cataract And Refractive Surgery
|
PDF
|
Bausch + Lomb Launches Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes
|
07/12/21
|
Bausch + Lomb Launches Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes
|
PDF
|
Bausch + Lomb Completes Enrollment Of Second Phase 3 Study For NOV03 (perfluorohexyloctane)
|
07/07/21
|
Bausch + Lomb Completes Enrollment Of Second Phase 3 Study For NOV03 (perfluorohexyloctane)
|
PDF
|
Bausch Health Companies Inc. Will Release Second-Quarter 2021 Financial Results On August 3
|
07/06/21
|
Bausch Health Companies Inc. Will Release Second-Quarter 2021 Financial Results On August 3
|
PDF
|
Bausch Health To Reduce Debt By $150 Million Using Cash Generated From Operations
|
07/01/21
|
Bausch Health To Reduce Debt By $150 Million Using Cash Generated From Operations
|
PDF
|
Bausch + Lomb Expands Parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses
|
06/23/21
|
Bausch + Lomb Expands Parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses
|
PDF
|
Bausch Health Announces Extension Of Its Tender Offer For Cash Tender Offer For Senior Secured Notes By One Business Day To Reflect The Federal Holiday On June 18, 2021
|
06/22/21
|
Bausch Health Announces Extension Of Its Tender Offer For Cash Tender Offer For Senior Secured Notes By One Business Day To Reflect The Federal Holiday On June 18, 2021
|
PDF
|
Bausch Health Announces D. Robert Hale Has Resigned From Its Board Of Directors
|
06/21/21
|
Bausch Health Announces D. Robert Hale Has Resigned From Its Board Of Directors
|
PDF
|
Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE™ Clinical Decision Support Software
|
06/08/21
|
Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE™ Clinical Decision Support Software
|
PDF
|
Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offer For Senior Secured Notes
|
06/07/21
|
Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offer For Senior Secured Notes
|
PDF
|
Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)
|
06/02/21
|
Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)
|
PDF
|
Bausch + Lomb and Prevent Blindness Launch Educational Campaign During Cataract Awareness Month
|
06/01/21
|
Bausch + Lomb and Prevent Blindness Launch Educational Campaign During Cataract Awareness Month
|
PDF
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
05/27/21
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
PDF
|
Bausch Health Announces Participation At The Jefferies Healthcare Conference
|
05/25/21
|
Bausch Health Announces Participation At The Jefferies Healthcare Conference
|
PDF
|
Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes
|
05/24/21
|
Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes
|
PDF
|
Bausch Health Commences Cash Tender Offer For Any And All Of Its 7.00% Senior Secured Notes Due 2024
|
05/24/21
|
Bausch Health Commences Cash Tender Offer For Any And All Of Its 7.00% Senior Secured Notes Due 2024
|
PDF
|
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes And Conditional Redemption Of Existing Senior Secured Notes
|
05/24/21
|
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes And Conditional Redemption Of Existing Senior Secured Notes
|
PDF
|
Salix Will Feature New Data At Digestive Disease Week® 2021
|
05/17/21
|
Salix Will Feature New Data At Digestive Disease Week® 2021
|
PDF
|
New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced Age-Related Macular Degeneration Progression
|
05/11/21
|
New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced Age-Related Macular Degeneration Progression
|
PDF
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
05/06/21
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
Bausch Health Companies Inc. Announces First-Quarter 2021 Results
|
05/04/21
|
Bausch Health Companies Inc. Announces First-Quarter 2021 Results
|
PDF
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
05/03/21
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
PDF
|
Bausch + Lomb Will Present New Scientific Data And Analyses On Products And Pipeline Programs During The Association For Research In Vision And Ophthalmology Meeting
|
04/29/21
|
Bausch + Lomb Will Present New Scientific Data And Analyses On Products And Pipeline Programs During The Association For Research In Vision And Ophthalmology Meeting
|
PDF
|
Bausch Health Announces 2021 Annual Meeting of Shareholder Results
|
04/28/21
|
Bausch Health Announces 2021 Annual Meeting of Shareholder Results
|
PDF
|
Bausch Health Issues Form 8-K for 2021 Annual Meeting of Shareholders Presentation
|
04/27/21
|
Bausch Health Issues Form 8-K for 2021 Annual Meeting of Shareholders Presentation
|
PDF
|
Ortho Dermatologics Announces Statistically Significant Topline Results From Second Pivotal Phase 3 Clinical Trial Evaluating IDP-126 Gel In Acne Vulgaris
|
04/22/21
|
Ortho Dermatologics Announces Statistically Significant Topline Results From Second Pivotal Phase 3 Clinical Trial Evaluating IDP-126 Gel In Acne Vulgaris
|
PDF
|
Ortho Dermatologics to Present New Data at the AAD VMX 2021, Virtual Meeting Experience
|
04/21/21
|
Ortho Dermatologics to Present New Data at the AAD VMX 2021, Virtual Meeting Experience
|
PDF
|
Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved In Brazil
|
04/16/21
|
Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved In Brazil
|
PDF
|
New Report Reveals That More Than One-Third Of IBS Patients Surveyed State It Has Been More Challenging To Manage Their Symptoms During The COVID-19 Pandemic
|
04/15/21
|
New Report Reveals That More Than One-Third Of IBS Patients Surveyed State It Has Been More Challenging To Manage Their Symptoms During The COVID-19 Pandemic
|
PDF
|
Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction
|
04/13/21
|
Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction
|
PDF
|
Bausch Health Companies Inc. Will Release First-Quarter 2021 Financial Results On May 4
|
04/09/21
|
Bausch Health Companies Inc. Will Release First-Quarter 2021 Financial Results On May 4
|
PDF
|
Bausch Health Launches ENVIVE™ Daily Probiotic Supplement
|
04/08/21
|
Bausch Health Launches ENVIVE™ Daily Probiotic Supplement
|
PDF
|
FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device
|
04/07/21
|
FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device
|
PDF
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
04/07/21
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
PDF
|
Bausch Health Agrees To Sell Amoun Pharmaceuticals
|
03/31/21
|
Bausch Health Agrees To Sell Amoun Pharmaceuticals
|
PDF
|
Salix Launches GastroHub for Advanced Practice Providers, an Educational Website Designed To Provide Nurse Practitioners and Physician Assistants With Relevant Information for Treating IBS-D and HE
|
03/30/21
|
Salix Launches GastroHub for Advanced Practice Providers, an Educational Website Designed To Provide Nurse Practitioners and Physician Assistants With Relevant Information for Treating IBS-D and HE
|
PDF
|
Bausch Health Announces CFO Succession Plan
|
03/11/21
|
Bausch Health Announces CFO Succession Plan
|
PDF
|
Bausch Health Publishes Pipeline Update For The Barclays Global Healthcare Conference
|
03/09/21
|
Bausch Health Publishes Pipeline Update For The Barclays Global Healthcare Conference
|
PDF
|
Solta Medical Announces the U.S. Launch of The Clear + Brilliant® Touch Laser
|
03/08/21
|
Solta Medical Announces the U.S. Launch of The Clear + Brilliant® Touch Laser
|
PDF
|
Colon Cancer Coalition and Salix to Launch a Year-Long Campaign to Raise Awareness About the Importance of Colorectal Cancer Screenings
|
03/01/21
|
Colon Cancer Coalition and Salix to Launch a Year-Long Campaign to Raise Awareness About the Importance of Colorectal Cancer Screenings
|
PDF
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
02/26/21
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
PDF
|
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2020 Results And Provides 2021 Guidance
|
02/24/21
|
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2020 Results And Provides 2021 Guidance
|
PDF
|
Bausch Health Announces Agreement With Carl C. Icahn
|
02/24/21
|
Bausch Health Announces Agreement With Carl C. Icahn
|
PDF
|
Bausch + Lomb Launches Alaway® Preservative Free Antihistamine Eye Drops
|
02/23/21
|
Bausch + Lomb Launches Alaway® Preservative Free Antihistamine Eye Drops
|
PDF
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
02/22/21
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
PDF
|
Salix Announces 2021 Gastrointestinal Health Scholars Program
|
02/18/21
|
Salix Announces 2021 Gastrointestinal Health Scholars Program
|
PDF
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
02/16/21
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
Bausch Health Responds To Schedule 13D Filing From Icahn Capital LP
|
02/11/21
|
Bausch Health Responds To Schedule 13D Filing From Icahn Capital LP
|
PDF
|
Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea
|
02/09/21
|
Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea
|
PDF
|
Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Program
|
02/02/21
|
Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Program
|
PDF
|
Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Age-Related Macular Degeneration (AMD)
|
02/01/21
|
Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Age-Related Macular Degeneration (AMD)
|
PDF
|
Bausch Health Companies Inc. Will Release Fourth-Quarter And Full-Year 2020 Financial Results On February 24
|
01/27/21
|
Bausch Health Companies Inc. Will Release Fourth-Quarter And Full-Year 2020 Financial Results On February 24
|
PDF
|
South Korea's MFDS Approves LUMIFY® Eye Drops
|
01/21/21
|
South Korea's MFDS Approves LUMIFY® Eye Drops
|
PDF
|
Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses To Be Presented At The Virtual Global Specialty Lens Symposium
|
01/20/21
|
Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses To Be Presented At The Virtual Global Specialty Lens Symposium
|
PDF
|
Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (perfluorohexyloctane)
|
01/19/21
|
Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (perfluorohexyloctane)
|
PDF
|
Bausch Health Provides Preliminary Update On Fourth-Quarter And Full-Year 2020 Financial Results And Business Recovery
|
01/12/21
|
Bausch Health Provides Preliminary Update On Fourth-Quarter And Full-Year 2020 Financial Results And Business Recovery
|
PDF
|
Bausch Health To Participate At The 39th Annual J.P. Morgan Healthcare Conference
|
01/06/21
|
Bausch Health To Participate At The 39th Annual J.P. Morgan Healthcare Conference
|
PDF
|
Bausch Health's DEXAVEN (Dexamethasone Phosphate) Receives New Indication In Poland To Treat Patients With SARS-CoV-2 (COVID-19)
|
12/30/20
|
Bausch Health's DEXAVEN (Dexamethasone Phosphate) Receives New Indication In Poland To Treat Patients With SARS-CoV-2 (COVID-19)
|
PDF
|
Bausch Health To Reduce Debt By $275 Million
|
12/29/20
|
Bausch Health To Reduce Debt By $275 Million
|
PDF
|
Bausch Health Initiates Second Phase 3 Study For NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction
|
11/24/20
|
Bausch Health Initiates Second Phase 3 Study For NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction
|
PDF
|
Bausch Health Announces Pricing And Upsize Of Private Offering Of Senior Notes And Conditional Redemption Of Additional Series Of Existing Senior Notes
|
11/18/20
|
Bausch Health Announces Pricing And Upsize Of Private Offering Of Senior Notes And Conditional Redemption Of Additional Series Of Existing Senior Notes
|
PDF
|
Bausch Health Announces Launch Of Private Offering Of Senior Notes And Conditional Redemption Of Existing Senior Notes
|
11/18/20
|
Bausch Health Announces Launch Of Private Offering Of Senior Notes And Conditional Redemption Of Existing Senior Notes
|
PDF
|
Bausch Health Announces Investigational In Vitro Data Indicating Complete Inactivation Of SARS-CoV-2 With LUMIFY® And BESIVANCE® Eye Drops Preserved With Benzalkonium Chloride
|
11/16/20
|
Bausch Health Announces Investigational In Vitro Data Indicating Complete Inactivation Of SARS-CoV-2 With LUMIFY® And BESIVANCE® Eye Drops Preserved With Benzalkonium Chloride
|
PDF
|
Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Materials Recycled Through One By One Recycling Program
|
11/12/20
|
Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Materials Recycled Through One By One Recycling Program
|
PDF
|
Salix To Present Data At AASLD's The Liver Meeting Digital Experience
|
11/11/20
|
Salix To Present Data At AASLD's The Liver Meeting Digital Experience
|
PDF
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
11/10/20
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
Bausch Health Companies Inc. Announces Third-Quarter 2020 Results
|
11/03/20
|
Bausch Health Companies Inc. Announces Third-Quarter 2020 Results
|
PDF
|
Bausch Health's Rifaximin Receives FDA Orphan Designation For Sickle Cell Disease
|
10/29/20
|
Bausch Health's Rifaximin Receives FDA Orphan Designation For Sickle Cell Disease
|
PDF
|
Bausch Health To Reduce Debt By $150 Million Using Cash Generated From Operations
|
10/29/20
|
Bausch Health To Reduce Debt By $150 Million Using Cash Generated From Operations
|
PDF
|
Bausch + Lomb Introduces SimplifEYE™ IOL Delivery System For enVista® Toric And Monofocal Preloaded Intraocular Lenses
|
10/27/20
|
Bausch + Lomb Introduces SimplifEYE™ IOL Delivery System For enVista® Toric And Monofocal Preloaded Intraocular Lenses
|
PDF
|
Ortho Dermatologics To Present New Analyses At The Virtual Fall Clinical Dermatology Conference
|
10/26/20
|
Ortho Dermatologics To Present New Analyses At The Virtual Fall Clinical Dermatology Conference
|
PDF
|
Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeting
|
10/22/20
|
Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeting
|
PDF
|
Bausch Health And BHVI Announce Exclusive Global Licensing Agreement For Myopia Control Contact Lens
|
10/15/20
|
Bausch Health And BHVI Announce Exclusive Global Licensing Agreement For Myopia Control Contact Lens
|
PDF
|
Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12
|
10/12/20
|
Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12
|
PDF
|
Salix To Present Clinical Data At United European Gastroenterology Week Virtual 2020
|
10/08/20
|
Salix To Present Clinical Data At United European Gastroenterology Week Virtual 2020
|
PDF
|
Bausch Health Companies Inc. Provides Preliminary Update On Third-Quarter 2020 Financial Results And Business Recovery
|
10/08/20
|
Bausch Health Companies Inc. Provides Preliminary Update On Third-Quarter 2020 Financial Results And Business Recovery
|
PDF
|
Bausch + Lomb Announces New Scientific And Clinical Analyses To Be Presented On Bausch + Lomb Infuse™ Silicone Hydrogel Daily Disposable Contact Lenses During The American Academy Of Optometry Annual Meeting
|
10/06/20
|
Bausch + Lomb Announces New Scientific And Clinical Analyses To Be Presented On Bausch + Lomb Infuse™ Silicone Hydrogel Daily Disposable Contact Lenses During The American Academy Of Optometry Annual Meeting
|
PDF
|
Salix Supports Liver Awareness Month With New Educational Initiatives
|
10/05/20
|
Salix Supports Liver Awareness Month With New Educational Initiatives
|
PDF
|
Nielsen's BASES Names LUMIFY® Eye Drops To 2020 U.S. BASES Top 25 Breakthrough Innovations List
|
10/01/20
|
Nielsen's BASES Names LUMIFY® Eye Drops To 2020 U.S. BASES Top 25 Breakthrough Innovations List
|
PDF
|
FDA Approves Bausch + Lomb Alaway® Preservative Free (Ketotifen Fumarate) Ophthalmic Solution, 0.035%
|
09/25/20
|
FDA Approves Bausch + Lomb Alaway® Preservative Free (Ketotifen Fumarate) Ophthalmic Solution, 0.035%
|
PDF
|
Bausch Health Announces VYZULTA® (Latanoprostene Bunod Ophthalmic Solution), 0.024%, is Now Approved In Seven Countries
|
09/24/20
|
Bausch Health Announces VYZULTA® (Latanoprostene Bunod Ophthalmic Solution), 0.024%, is Now Approved In Seven Countries
|
PDF
|
Bausch Health Releases Annual Corporate Social Responsibility Report
|
09/23/20
|
Bausch Health Releases Annual Corporate Social Responsibility Report
|
PDF
|
Bausch Health And Alfasigma Announce Resolution Of XIFAXAN® Intellectual Property Litigation
|
09/22/20
|
Bausch Health And Alfasigma Announce Resolution Of XIFAXAN® Intellectual Property Litigation
|
PDF
|
Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics
|
09/21/20
|
Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics
|
PDF
|
Bausch Health Provides Company Update At 18th Annual Morgan Stanley Global Healthcare Conference
|
09/16/20
|
Bausch Health Provides Company Update At 18th Annual Morgan Stanley Global Healthcare Conference
|
PDF
|
Bausch Foundation Releases Inaugural Activity Report
|
09/10/20
|
Bausch Foundation Releases Inaugural Activity Report
|
PDF
|
Bausch Health To Participate At The 18th Annual Morgan Stanley Global Healthcare Conference
|
09/09/20
|
Bausch Health To Participate At The 18th Annual Morgan Stanley Global Healthcare Conference
|
PDF
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
08/31/20
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
PDF
|
Australia's TGA Approves BAUSCH + LOMB ULTRA® ONE DAY Silicone Hydrogel Daily Disposable Contact Lenses
|
08/18/20
|
Australia's TGA Approves BAUSCH + LOMB ULTRA® ONE DAY Silicone Hydrogel Daily Disposable Contact Lenses
|
PDF
|
Bausch + Lomb Launches Innovative Bausch + Lomb INFUSE™ Silicone Hydrogel (SiHy) Daily Disposable Contact Lenses
|
08/17/20
|
Bausch + Lomb Launches Innovative Bausch + Lomb INFUSE™ Silicone Hydrogel (SiHy) Daily Disposable Contact Lenses
|
PDF
|
Health Canada Approves BAUSCH + LOMB ULTRA ONE DAY® Silicone Hydrogel Daily Disposable Contact Lenses
|
08/11/20
|
Health Canada Approves BAUSCH + LOMB ULTRA ONE DAY® Silicone Hydrogel Daily Disposable Contact Lenses
|
PDF
|
Bausch Health Announces Its Intention To Spin Off Its Eye Health Business Into An Independent Publicly Traded Company
|
08/06/20
|
Bausch Health Announces Its Intention To Spin Off Its Eye Health Business Into An Independent Publicly Traded Company
|
PDF
|
Bausch Health Companies Inc. Announces Second-Quarter 2020 Results
|
08/06/20
|
Bausch Health Companies Inc. Announces Second-Quarter 2020 Results
|
PDF
|
Bausch Health Resolves Canadian Securities Class Action
|
08/05/20
|
Bausch Health Resolves Canadian Securities Class Action
|
PDF
|
Bausch Health Resolves Legacy SEC Investigation
|
07/31/20
|
Bausch Health Resolves Legacy SEC Investigation
|
PDF
|
Ortho Dermatologics Announces 2020 Aspire Higher Scholarship Recipients
|
07/28/20
|
Ortho Dermatologics Announces 2020 Aspire Higher Scholarship Recipients
|
PDF
|
Bausch Health Companies Inc. Will Release Second-Quarter 2020 Financial Results On August 6
|
07/23/20
|
Bausch Health Companies Inc. Will Release Second-Quarter 2020 Financial Results On August 6
|
PDF
|
Ortho Dermatologics Launches ARAZLO™ (tazarotene) Lotion, 0.045%, In The United States
|
06/23/20
|
Ortho Dermatologics Launches ARAZLO™ (tazarotene) Lotion, 0.045%, In The United States
|
PDF
|
BAUSCH + LOMB ULTRA® Silicone Hydrogel Contact Lenses Receive Approval In China
|
06/17/20
|
BAUSCH + LOMB ULTRA® Silicone Hydrogel Contact Lenses Receive Approval In China
|
PDF
|
Bausch Health to Participate at Goldman Sachs Annual Leveraged Finance Conference
|
06/16/20
|
Bausch Health to Participate at Goldman Sachs Annual Leveraged Finance Conference
|
PDF
|
Salix Announces Inaugural Salix Gastrointestinal Health Scholars Program Recipients
|
06/15/20
|
Salix Announces Inaugural Salix Gastrointestinal Health Scholars Program Recipients
|
PDF
|
FDA Provides 510(k) Clearance For BAUSCH + LOMB INFUSE™ Daily Disposable Silicone Hydrogel (SiHy Daily) Contact Lenses
|
06/04/20
|
FDA Provides 510(k) Clearance For BAUSCH + LOMB INFUSE™ Daily Disposable Silicone Hydrogel (SiHy Daily) Contact Lenses
|
PDF
|
Bausch + Lomb Announces The European Launch Of LuxSmart™ And LuxGood™ Preloaded Intraocular Lenses
|
05/27/20
|
Bausch + Lomb Announces The European Launch Of LuxSmart™ And LuxGood™ Preloaded Intraocular Lenses
|
PDF
|
Bausch Health To Participate At Goldman Sachs Annual Global Healthcare Conference
|
05/21/20
|
Bausch Health To Participate At Goldman Sachs Annual Global Healthcare Conference
|
PDF
|
Bausch Health Announces Pricing And Upsize Of Private Offering Of Senior Notes And Prepayment Of Term Loan 2022 Mandatory Amortization
|
05/11/20
|
Bausch Health Announces Pricing And Upsize Of Private Offering Of Senior Notes And Prepayment Of Term Loan 2022 Mandatory Amortization
|
PDF
|
Bausch Health Announces Launch of Private Offering of Senior Notes and Conditional Redemption of Existing Senior Secured Notes
|
05/11/20
|
Bausch Health Announces Launch of Private Offering of Senior Notes and Conditional Redemption of Existing Senior Secured Notes
|
PDF
|
Bausch Health Companies Inc. Announces First-Quarter 2020 Results
|
05/07/20
|
Bausch Health Companies Inc. Announces First-Quarter 2020 Results
|
PDF
|
Bausch Health And Alfasigma Announce Resolution Of XIFAXAN® Intellectual Property Litigation
|
05/06/20
|
Bausch Health And Alfasigma Announce Resolution Of XIFAXAN® Intellectual Property Litigation
|
PDF
|
Bausch Health To Participate at 2020 Bank of America Merrill Lynch Global Healthcare Conference
|
04/30/20
|
Bausch Health To Participate at 2020 Bank of America Merrill Lynch Global Healthcare Conference
|
PDF
|
Salix To Highlight New Data Across Its Portfolio Of Products At Digestive Disease Week 2020 Virtual Meeting
|
04/30/20
|
Salix To Highlight New Data Across Its Portfolio Of Products At Digestive Disease Week 2020 Virtual Meeting
|
PDF
|
Bausch Health Announces 2020 Annual Meeting Of Shareholder Results
|
04/29/20
|
Bausch Health Announces 2020 Annual Meeting Of Shareholder Results
|
PDF
|
FDA Approves Ortho Dermatologics' Labeling For JUBLIA® (efinaconazole) Topical Solution, 10%, In Patients As Young As Six Years Old
|
04/29/20
|
FDA Approves Ortho Dermatologics' Labeling For JUBLIA® (efinaconazole) Topical Solution, 10%, In Patients As Young As Six Years Old
|
PDF
|
Bausch Health Issues Form 8-K For 2020 Annual Meeting Of Shareholders Presentation
|
04/28/20
|
Bausch Health Issues Form 8-K For 2020 Annual Meeting Of Shareholders Presentation
|
PDF
|
Bausch Health Companies Inc. Will Release First-Quarter 2020 Financial Results On May 7
|
04/23/20
|
Bausch Health Companies Inc. Will Release First-Quarter 2020 Financial Results On May 7
|
PDF
|
Bausch + Lomb Announces Publication Of 10-Year Armor Study Results On Ocular Antibiotic Resistance In JAMA Ophthalmology
|
04/14/20
|
Bausch + Lomb Announces Publication Of 10-Year Armor Study Results On Ocular Antibiotic Resistance In JAMA Ophthalmology
|
PDF
|
Bausch Health Initiates VIRAZOLE® (Ribavirin for Inhalation Solution, USP) Clinical Study in Patients with COVID-19
|
04/13/20
|
Bausch Health Initiates VIRAZOLE® (Ribavirin for Inhalation Solution, USP) Clinical Study in Patients with COVID-19
|
PDF
|
Bausch Health Companies Inc. Will Hold Virtual Annual Meeting Of Shareholders On April 28
|
04/02/20
|
Bausch Health Companies Inc. Will Hold Virtual Annual Meeting Of Shareholders On April 28
|
PDF
|
Bausch Health Announces Favorable Topline Results From Study Evaluating Investigative Formulation of Rifaximin SSD IR to Treat Overt Hepatic Encephalopathy
|
03/31/20
|
Bausch Health Announces Favorable Topline Results From Study Evaluating Investigative Formulation of Rifaximin SSD IR to Treat Overt Hepatic Encephalopathy
|
PDF
|
Bausch Health Donates Health Care Products And Supplies Through Bausch Foundation In Response To COVID-19 Pandemic
|
03/24/20
|
Bausch Health Donates Health Care Products And Supplies Through Bausch Foundation In Response To COVID-19 Pandemic
|
PDF
|
Bausch Health To Reduce Debt By Approximately $100 Million Using Cash Generated From Operations
|
03/13/20
|
Bausch Health To Reduce Debt By Approximately $100 Million Using Cash Generated From Operations
|
PDF
|
Bausch Health Announces It Will No Longer Pursue Proposed Refinancing Transaction And Also Announces Cancellation Of Previously Delivered Notice Of Conditional Redemption
|
03/02/20
|
Bausch Health Announces It Will No Longer Pursue Proposed Refinancing Transaction And Also Announces Cancellation Of Previously Delivered Notice Of Conditional Redemption
|
PDF
|
Bausch Health Announces It Is Seeking A Refinancing Amendment To Its Existing Credit Agreement And Conditional Redemption Of Existing Senior Secured Notes
|
02/19/20
|
Bausch Health Announces It Is Seeking A Refinancing Amendment To Its Existing Credit Agreement And Conditional Redemption Of Existing Senior Secured Notes
|
PDF
|
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2019 Results And Provides 2020 Guidance
|
02/19/20
|
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2019 Results And Provides 2020 Guidance
|
PDF
|
Ortho Dermatologics Launches Telemedicine on Dermatology.com, U.S. Cash-Pay Prescription Program
|
02/18/20
|
Ortho Dermatologics Launches Telemedicine on Dermatology.com, U.S. Cash-Pay Prescription Program
|
PDF
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
02/12/20
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
PDF
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
02/04/20
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
Bausch + Lomb And Prevent Blindness Join Together To Raise Awareness And Provide Educational Resources For February's Age-Related Macular Degeneration Awareness Month
|
02/03/20
|
Bausch + Lomb And Prevent Blindness Join Together To Raise Awareness And Provide Educational Resources For February's Age-Related Macular Degeneration Awareness Month
|
PDF
|
Ortho Dermatologics Opens 2020 Aspire Higher Scholarship Program
|
02/03/20
|
Ortho Dermatologics Opens 2020 Aspire Higher Scholarship Program
|
PDF
|
Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology
|
01/28/20
|
Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology
|
PDF
|
Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2019 Financial Results on February 19
|
01/16/20
|
Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2019 Financial Results on February 19
|
PDF
|
Bausch Health Publishes Company Update for the 38th Annual J.P. Morgan Healthcare Conference
|
01/13/20
|
Bausch Health Publishes Company Update for the 38th Annual J.P. Morgan Healthcare Conference
|
PDF
|
Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Data On ARAZLO™ (tazarotene) Lotion, 0.045% In The Journal Of Drugs In Dermatology (JDD)
|
01/13/20
|
Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Data On ARAZLO™ (tazarotene) Lotion, 0.045% In The Journal Of Drugs In Dermatology (JDD)
|
PDF
|
Bausch + Lomb Launches Expanded Parameters for Biotrue® ONEday for Astigmatism Daily Disposable Contact Lenses
|
01/06/20
|
Bausch + Lomb Launches Expanded Parameters for Biotrue® ONEday for Astigmatism Daily Disposable Contact Lenses
|
PDF
|
Bausch Health To Participate At The 38th Annual J.P. Morgan Healthcare Conference
|
01/06/20
|
Bausch Health To Participate At The 38th Annual J.P. Morgan Healthcare Conference
|
PDF
|
Bausch Health Licenses Novaliq's NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction
|
12/20/19
|
Bausch Health Licenses Novaliq's NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction
|
PDF
|
Bausch Health Announces Resolution Of BRYHALI® (Halobetasol Propionate) Lotion, 0.01%, Intellectual Property Litigation With Glenmark
|
12/20/19
|
Bausch Health Announces Resolution Of BRYHALI® (Halobetasol Propionate) Lotion, 0.01%, Intellectual Property Litigation With Glenmark
|
PDF
|
FDA Approves Ortho Dermatologics' ARAZLOTM (Tazarotene) Lotion, 0.045%, For Acne Vulgaris
|
12/19/19
|
FDA Approves Ortho Dermatologics' ARAZLOTM (Tazarotene) Lotion, 0.045%, For Acne Vulgaris
|
PDF
|
Bausch Health Announces Conditional Redemption Of Existing Senior Notes
|
12/18/19
|
Bausch Health Announces Conditional Redemption Of Existing Senior Notes
|
PDF
|
Bausch Health Announces Pricing of Private Offering of Senior Notes
|
12/17/19
|
Bausch Health Announces Pricing of Private Offering of Senior Notes
|
PDF
|
Bausch + Lomb Initiates Clinical Trial Evaluating New Cohesive Ophthalmic Viscosurgical Device (OVD) For Use In Cataract Surgery
|
12/17/19
|
Bausch + Lomb Initiates Clinical Trial Evaluating New Cohesive Ophthalmic Viscosurgical Device (OVD) For Use In Cataract Surgery
|
PDF
|
Bausch Health Announces Launch Of Private Offering Of Senior Notes
|
12/17/19
|
Bausch Health Announces Launch Of Private Offering Of Senior Notes
|
PDF
|
Bausch Health Resolves "Stock Drop" Litigation Initially Filed in October 2015
|
12/16/19
|
Bausch Health Resolves "Stock Drop" Litigation Initially Filed in October 2015
|
PDF
|
Bausch + Lomb Introduces enVista® Toric MX60ET Intraocular Lens With StableFlex™ Technology
|
12/11/19
|
Bausch + Lomb Introduces enVista® Toric MX60ET Intraocular Lens With StableFlex™ Technology
|
PDF
|
Bausch + Lomb And TerraCycle Announce Donation Of New Custom Training Modules Incorporating Used Contact Lens Materials To Guide Dog Foundation
|
11/13/19
|
Bausch + Lomb And TerraCycle Announce Donation Of New Custom Training Modules Incorporating Used Contact Lens Materials To Guide Dog Foundation
|
PDF
|
Bausch Health Companies Announces Participation in Upcoming Investor Conferences
|
11/11/19
|
Bausch Health Companies Announces Participation in Upcoming Investor Conferences
|
PDF
|
Bausch Health Companies Inc. Announces Third-Quarter 2019 Results and Raises Full-Year Revenue and Adjusted EBITDA (non-GAAP) Guidance Ranges
|
11/04/19
|
Bausch Health Companies Inc. Announces Third-Quarter 2019 Results and Raises Full-Year Revenue and Adjusted EBITDA (non-GAAP) Guidance Ranges
|
PDF
|
Salix Announces Issuance of an Additional XIFAXAN® Patent
|
10/31/19
|
Salix Announces Issuance of an Additional XIFAXAN® Patent
|
PDF
|
Salix Pharmaceuticals Announces Inaugural Scholarship Program To Commemorate Its 30th Anniversary
|
10/30/19
|
Salix Pharmaceuticals Announces Inaugural Scholarship Program To Commemorate Its 30th Anniversary
|
PDF
|
Salix Pharmaceuticals to Present New Clinical Data at the American College of Gastroenterology (ACG) Annual Meeting
|
10/28/19
|
Salix Pharmaceuticals to Present New Clinical Data at the American College of Gastroenterology (ACG) Annual Meeting
|
PDF
|
Bausch Health Licenses Clearside Biomedical's XIPERE™ (Triamcinolone Acetonide Suprachoroidal Injectable Suspension), An Investigational Treatment For Macular Edema Associated With Uveitis
|
10/23/19
|
Bausch Health Licenses Clearside Biomedical's XIPERE™ (Triamcinolone Acetonide Suprachoroidal Injectable Suspension), An Investigational Treatment For Macular Edema Associated With Uveitis
|
PDF
|
Bausch + Lomb Introduces PreserVision® AREDS 2 Formula Minigel Eye Vitamins
|
10/21/19
|
Bausch + Lomb Introduces PreserVision® AREDS 2 Formula Minigel Eye Vitamins
|
PDF
|
Bausch Health's Ortho Dermatologics Business To Present Data At The Fall Clinical Dermatology Conference
|
10/15/19
|
Bausch Health's Ortho Dermatologics Business To Present Data At The Fall Clinical Dermatology Conference
|
PDF
|
Ortho Dermatologics Announces 2019 Aspire Higher Scholarship Recipients
|
10/10/19
|
Ortho Dermatologics Announces 2019 Aspire Higher Scholarship Recipients
|
PDF
|
Bausch + Lomb Announces New Scientific And Clinical Analyses To Be Presented During The American Academy Of Ophthalmology And American Academy Of Optometry Annual Meetings
|
10/07/19
|
Bausch + Lomb Announces New Scientific And Clinical Analyses To Be Presented During The American Academy Of Ophthalmology And American Academy Of Optometry Annual Meetings
|
PDF
|
Bausch Health Companies Inc. Will Release Third-Quarter 2019 Financial Results on November 4
|
10/04/19
|
Bausch Health Companies Inc. Will Release Third-Quarter 2019 Financial Results on November 4
|
PDF
|
Bausch Health Files Lawsuit Against Sandoz For Infringement Of Patents Protecting XIFAXAN® 550 mg Tablets
|
10/01/19
|
Bausch Health Files Lawsuit Against Sandoz For Infringement Of Patents Protecting XIFAXAN® 550 mg Tablets
|
PDF
|
Bausch Health Releases 2018 Corporate Social Responsibility Report
|
09/10/19
|
Bausch Health Releases 2018 Corporate Social Responsibility Report
|
PDF
|
Bausch Health To Reduce Debt By Approximately $200 Million Using Cash Flow From Operations
|
09/03/19
|
Bausch Health To Reduce Debt By Approximately $200 Million Using Cash Flow From Operations
|
PDF
|
Bausch Health Companies Announces Participation In Upcoming Investor Conferences
|
08/29/19
|
Bausch Health Companies Announces Participation In Upcoming Investor Conferences
|
PDF
|
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-123 Treatment For Acne Vulgaris In Lotion Form
|
08/07/19
|
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-123 Treatment For Acne Vulgaris In Lotion Form
|
PDF
|
Bausch Health Companies Inc. Announces Second-Quarter 2019 Results And Raises Full-Year Guidance
|
08/06/19
|
Bausch Health Companies Inc. Announces Second-Quarter 2019 Results And Raises Full-Year Guidance
|
PDF
|
Bausch Health Expands Dermatology Cash-Pay Prescription Program to Walgreens Stores Nationwide
|
08/01/19
|
Bausch Health Expands Dermatology Cash-Pay Prescription Program to Walgreens Stores Nationwide
|
PDF
|
Bausch Health Provides APRISO® Intellectual Property Litigation Update
|
07/31/19
|
Bausch Health Provides APRISO® Intellectual Property Litigation Update
|
PDF
|
Bausch Health to Reduce Debt by Additional $100 Million Using Cash Flow from Operations
|
07/29/19
|
Bausch Health to Reduce Debt by Additional $100 Million Using Cash Flow from Operations
|
PDF
|
Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets
|
07/17/19
|
Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets
|
PDF
|
Bausch + Lomb Announces U.S. Launch Of Ocuvite® Eye Performance Vitamins
|
07/09/19
|
Bausch + Lomb Announces U.S. Launch Of Ocuvite® Eye Performance Vitamins
|
PDF
|
Bausch Health Companies Inc. Will Release Second-Quarter 2019 Financial Results On August 6
|
07/08/19
|
Bausch Health Companies Inc. Will Release Second-Quarter 2019 Financial Results On August 6
|
PDF
|
Bausch Health To Reduce Debt By Additional $100 Million Using Cash Generated From Operations
|
06/25/19
|
Bausch Health To Reduce Debt By Additional $100 Million Using Cash Generated From Operations
|
PDF
|
Bausch Health Announces U.S. Launch of DUOBRII™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis in Adults
|
06/25/19
|
Bausch Health Announces U.S. Launch of DUOBRII™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis in Adults
|
PDF
|
Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses Now Available In the United States
|
06/19/19
|
Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses Now Available In the United States
|
PDF
|
Bausch Health Companies Announces Participation in Upcoming Investor Conferences
|
05/29/19
|
Bausch Health Companies Announces Participation in Upcoming Investor Conferences
|
PDF
|
Bausch Health Announces Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes
|
05/23/19
|
Bausch Health Announces Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes
|
PDF
|
Bausch Health Announces Pricing Of Private Offering Of Senior Notes
|
05/09/19
|
Bausch Health Announces Pricing Of Private Offering Of Senior Notes
|
PDF
|
Bausch Health Commences Cash Tender Offers For Up To $1,500,000,000 Aggregate Principal Amount Of Outstanding Notes Of Certain Series
|
05/09/19
|
Bausch Health Commences Cash Tender Offers For Up To $1,500,000,000 Aggregate Principal Amount Of Outstanding Notes Of Certain Series
|
PDF
|
Bausch Health Announces Launch Of Private Offering Of Senior Notes
|
05/09/19
|
Bausch Health Announces Launch Of Private Offering Of Senior Notes
|
PDF
|
Bausch Health Companies Inc. Announces First-Quarter 2019 Results And Raises Full-Year Guidance
|
05/06/19
|
Bausch Health Companies Inc. Announces First-Quarter 2019 Results And Raises Full-Year Guidance
|
PDF
|
Bausch Health Issues Form 8K For 2019 Annual Meeting Of Shareholders Presentation
|
04/30/19
|
Bausch Health Issues Form 8K For 2019 Annual Meeting Of Shareholders Presentation
|
PDF
|
Bausch + Lomb Announces New Scientific Analyses Featuring Surgical And Pharmaceutical Products Will Be Presented During The Annual Meeting Of The American Society Of Cataract And Refractive Surgery
|
04/29/19
|
Bausch + Lomb Announces New Scientific Analyses Featuring Surgical And Pharmaceutical Products Will Be Presented During The Annual Meeting Of The American Society Of Cataract And Refractive Surgery
|
PDF
|
New Scientific And Clinical Analyses Regarding Bausch + Lomb Surgical And Pharmaceutical Products To Be Presented During The Association For Research In Vision And Ophthalmology Meeting
|
04/26/19
|
New Scientific And Clinical Analyses Regarding Bausch + Lomb Surgical And Pharmaceutical Products To Be Presented During The Association For Research In Vision And Ophthalmology Meeting
|
PDF
|
FDA Approves Bausch Health's DUOBRII™ (Halobetasol Propionate And Tazarotene) Lotion 0.01%/0.045% For Plaque Psoriasis In Adults
|
04/25/19
|
FDA Approves Bausch Health's DUOBRII™ (Halobetasol Propionate And Tazarotene) Lotion 0.01%/0.045% For Plaque Psoriasis In Adults
|
PDF
|
Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease
|
04/25/19
|
Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease
|
PDF
|
Bausch Health Companies Announces Participation In Upcoming Investor Conferences
|
04/24/19
|
Bausch Health Companies Announces Participation In Upcoming Investor Conferences
|
PDF
|
Bausch + Lomb Reports More Than 9.2 Million Units Of Contact Lens Materials Diverted From Waste Stream Through ONE By ONE Recycling Program
|
04/22/19
|
Bausch + Lomb Reports More Than 9.2 Million Units Of Contact Lens Materials Diverted From Waste Stream Through ONE By ONE Recycling Program
|
PDF
|
Bausch Health Companies Inc. Will Release First-Quarter 2019 Financial Results On May 6
|
04/08/19
|
Bausch Health Companies Inc. Will Release First-Quarter 2019 Financial Results On May 6
|
PDF
|
Bausch + Lomb Announces The U.S. Launch Of LOTEMAX® SM (Loteprednol Etabonate Ophthalmic Gel) 0.38% For The Treatment Of Postoperative Inflammation And Pain Following Ocular Surgery
|
04/02/19
|
Bausch + Lomb Announces The U.S. Launch Of LOTEMAX® SM (Loteprednol Etabonate Ophthalmic Gel) 0.38% For The Treatment Of Postoperative Inflammation And Pain Following Ocular Surgery
|
PDF
|
Salix Enters Into License Agreement With The University Of California To Develop And Commercialize Novel Compound For The Treatment Of Non-alcoholic Fatty Liver Disease And Non-alcoholic Steatohepatitis
|
04/01/19
|
Salix Enters Into License Agreement With The University Of California To Develop And Commercialize Novel Compound For The Treatment Of Non-alcoholic Fatty Liver Disease And Non-alcoholic Steatohepatitis
|
PDF
|
Ortho Dermatologics Launches 2019 Aspire Higher Scholarship Program For Students With Dermatologic Conditions
|
03/11/19
|
Ortho Dermatologics Launches 2019 Aspire Higher Scholarship Program For Students With Dermatologic Conditions
|
PDF
|
Bausch Health Announces Closing Of Senior Secured Notes And Add-On Unsecured Notes, As Well As Redemption Of Existing Senior Notes
|
03/08/19
|
Bausch Health Announces Closing Of Senior Secured Notes And Add-On Unsecured Notes, As Well As Redemption Of Existing Senior Notes
|
PDF
|
Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offers And Consent Solicitation For Senior Notes
|
03/08/19
|
Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offers And Consent Solicitation For Senior Notes
|
PDF
|
Bausch Health Completes Acquisition Of Certain Assets Of Synergy Pharmaceuticals Inc.
|
03/06/19
|
Bausch Health Completes Acquisition Of Certain Assets Of Synergy Pharmaceuticals Inc.
|
PDF
|
Ortho Dermatologics To Present New Analyses At The American Academy Of Dermatology Annual Meeting
|
02/28/19
|
Ortho Dermatologics To Present New Analyses At The American Academy Of Dermatology Annual Meeting
|
PDF
|
Bausch Health to Acquire Certain Assets of Synergy Pharmaceuticals Inc.
|
02/26/19
|
Bausch Health to Acquire Certain Assets of Synergy Pharmaceuticals Inc.
|
PDF
|
Bausch + Lomb Announces FDA Approval Of LOTEMAX® SM (loteprednol Etabonate Ophthalmic Gel) 0.38% For The Treatment Of Postoperative Inflammation And Pain Following Ocular Surgery
|
02/25/19
|
Bausch + Lomb Announces FDA Approval Of LOTEMAX® SM (loteprednol Etabonate Ophthalmic Gel) 0.38% For The Treatment Of Postoperative Inflammation And Pain Following Ocular Surgery
|
PDF
|
Bausch Health Announces Upsize Of Cash Tender Offers And Consent Solicitation To $1,500,000,000 Aggregate Purchase Price
|
02/22/19
|
Bausch Health Announces Upsize Of Cash Tender Offers And Consent Solicitation To $1,500,000,000 Aggregate Purchase Price
|
PDF
|
Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes And Add-On Unsecured Notes
|
02/22/19
|
Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes And Add-On Unsecured Notes
|
PDF
|
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes And Add-On Unsecured Notes
|
02/22/19
|
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes And Add-On Unsecured Notes
|
PDF
|
Bausch Health Commences Cash Tender Offers And Consent Solicitation For Up To $1,250,000,000 Aggregate Purchase Price
|
02/22/19
|
Bausch Health Commences Cash Tender Offers And Consent Solicitation For Up To $1,250,000,000 Aggregate Purchase Price
|
PDF
|
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2018 Results And Provides 2019 Guidance
|
02/20/19
|
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2018 Results And Provides 2019 Guidance
|
PDF
|
Bausch Health Acquires Eton Pharmaceuticals' EM-100 Investigational Eye Drop For The Treatment Of Itchy Eyes Associated With Allergies
|
02/19/19
|
Bausch Health Acquires Eton Pharmaceuticals' EM-100 Investigational Eye Drop For The Treatment Of Itchy Eyes Associated With Allergies
|
PDF
|
Bausch Health Provides Update For DUOBRII Filing
|
02/15/19
|
Bausch Health Provides Update For DUOBRII Filing
|
PDF
|
Bausch + Lomb Receives 510(k) Clearance For Use Of The Tangible® Hydra-PEG® Custom Contact Lens Coating Technology On Several Of Its Boston® Gas Permeable Lens Materials And Zenlens™ Family Of Scleral Lenses
|
02/13/19
|
Bausch + Lomb Receives 510(k) Clearance For Use Of The Tangible® Hydra-PEG® Custom Contact Lens Coating Technology On Several Of Its Boston® Gas Permeable Lens Materials And Zenlens™ Family Of Scleral Lenses
|
PDF
|
Bausch + Lomb Launches SightMatters.com To Help People Living With Age-Related Macular Degeneration Take Control Of Their Condition
|
02/04/19
|
Bausch + Lomb Launches SightMatters.com To Help People Living With Age-Related Macular Degeneration Take Control Of Their Condition
|
PDF
|
Bausch Health Companies Announces Participation In Upcoming Investor Conferences
|
02/01/19
|
Bausch Health Companies Announces Participation In Upcoming Investor Conferences
|
PDF
|
Bausch Health Reduces Debt By Additional $100 Million
|
01/29/19
|
Bausch Health Reduces Debt By Additional $100 Million
|
PDF
|
Bausch Health Companies Inc. Will Release Fourth-Quarter And Full-Year 2018 Financial Results On February 20
|
01/18/19
|
Bausch Health Companies Inc. Will Release Fourth-Quarter And Full-Year 2018 Financial Results On February 20
|
PDF
|
Bausch Health Provides Company Update At The 37th Annual J.P. Morgan Healthcare Conference
|
01/07/19
|
Bausch Health Provides Company Update At The 37th Annual J.P. Morgan Healthcare Conference
|
PDF
|
Bausch Health To Present At The 37th Annual J.P. Morgan Healthcare Conference
|
01/02/19
|
Bausch Health To Present At The 37th Annual J.P. Morgan Healthcare Conference
|
PDF
|
Bausch Health To Reduce Debt By Additional $76 Million, Bringing Total Debt Repayment In Quarter To Approximately $400 Million
|
12/19/18
|
Bausch Health To Reduce Debt By Additional $76 Million, Bringing Total Debt Repayment In Quarter To Approximately $400 Million
|
PDF
|
Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.
|
12/12/18
|
Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.
|
PDF
|
Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses
|
12/05/18
|
Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses
|
PDF
|
Bausch Health Announces Redemption Of $200 Million Aggregate Principal Amount Of Its Outstanding 5.625% Senior Notes Due 2021
|
11/30/18
|
Bausch Health Announces Redemption Of $200 Million Aggregate Principal Amount Of Its Outstanding 5.625% Senior Notes Due 2021
|
PDF
|
Bausch Health Announces Closing Of Incremental Amendment To Its Existing Credit Agreement And Redemption Of Its 7.500% Senior Notes Due 2021
|
11/27/18
|
Bausch Health Announces Closing Of Incremental Amendment To Its Existing Credit Agreement And Redemption Of Its 7.500% Senior Notes Due 2021
|
PDF
|
Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offer And Consent Solicitation For Any And All Of Its 7.500% Senior Notes Due 2021
|
11/21/18
|
Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offer And Consent Solicitation For Any And All Of Its 7.500% Senior Notes Due 2021
|
PDF
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
11/19/18
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
Bausch + Lomb Reports More Than Five Million Units Of Contact Lens Materials Recycled By Second Anniversary Of ONE By ONE Recycling Program
|
11/15/18
|
Bausch + Lomb Reports More Than Five Million Units Of Contact Lens Materials Recycled By Second Anniversary Of ONE By ONE Recycling Program
|
PDF
|
Bausch Health Will Expand Contact Lens Manufacturing Facilities In Rochester, NY And Waterford, Ireland
|
11/13/18
|
Bausch Health Will Expand Contact Lens Manufacturing Facilities In Rochester, NY And Waterford, Ireland
|
PDF
|
Bausch Health Commences Cash Tender Offer And Consent Solicitation For Any And All Of Its 7.500% Senior Notes Due 2021
|
11/07/18
|
Bausch Health Commences Cash Tender Offer And Consent Solicitation For Any And All Of Its 7.500% Senior Notes Due 2021
|
PDF
|
Bausch Health To Seek Incremental Amendment To Its Existing Credit Agreement
|
11/07/18
|
Bausch Health To Seek Incremental Amendment To Its Existing Credit Agreement
|
PDF
|
Bausch Health To Participate At The Stifel 2018 Healthcare Conference
|
11/07/18
|
Bausch Health To Participate At The Stifel 2018 Healthcare Conference
|
PDF
|
Bausch Health Announces U.S. Launch Of BRYHALI™ (halobetasol propionate) Lotion, 0.01%, For Plaque Psoriasis In Adults
|
11/07/18
|
Bausch Health Announces U.S. Launch Of BRYHALI™ (halobetasol propionate) Lotion, 0.01%, For Plaque Psoriasis In Adults
|
PDF
|
Bausch Health Companies Inc. Announces Third-Quarter 2018 Results
|
11/06/18
|
Bausch Health Companies Inc. Announces Third-Quarter 2018 Results
|
PDF
|
Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United States
|
10/30/18
|
Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United States
|
PDF
|
Dr. Andrew C. Von Eschenbach Joins Bausch Health Board Of Directors
|
10/30/18
|
Dr. Andrew C. Von Eschenbach Joins Bausch Health Board Of Directors
|
PDF
|
Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease
|
10/29/18
|
Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease
|
PDF
|
Bausch + Lomb To Launch First-In-Class Surgical Support Applications For Stellaris Elite™ Vision Enhancement System On IBM Cloud
|
10/24/18
|
Bausch + Lomb To Launch First-In-Class Surgical Support Applications For Stellaris Elite™ Vision Enhancement System On IBM Cloud
|
PDF
|
Bausch Health Announces Endowment With The University Of Missouri To Support Student Scholarships
|
10/23/18
|
Bausch Health Announces Endowment With The University Of Missouri To Support Student Scholarships
|
PDF
|
Bausch Health's Ortho Dermatologics Business To Present New Scientific Data During The Fall Clinical Dermatology Conference
|
10/15/18
|
Bausch Health's Ortho Dermatologics Business To Present New Scientific Data During The Fall Clinical Dermatology Conference
|
PDF
|
Bausch Health Companies Inc. Will Release Third-Quarter 2018 Financial Results On November 6
|
10/12/18
|
Bausch Health Companies Inc. Will Release Third-Quarter 2018 Financial Results On November 6
|
PDF
|
Bausch Health Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On ALTRENO™ (tretinoin) Lotion, 0.05% In The Journal Of Drugs In Dermatology
|
10/11/18
|
Bausch Health Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On ALTRENO™ (tretinoin) Lotion, 0.05% In The Journal Of Drugs In Dermatology
|
PDF
|
Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting
|
10/08/18
|
Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting
|
PDF
|
Bausch Health's BRYHALI™(halobetasol propionate) Lotion, 0.01%, Receives Tentative FDA Approval For Plaque Psoriasis In Adults
|
10/08/18
|
Bausch Health's BRYHALI™(halobetasol propionate) Lotion, 0.01%, Receives Tentative FDA Approval For Plaque Psoriasis In Adults
|
PDF
|
Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On Bryhali™* (Halobetasol Propionate) Lotion, 0.01% In The Journal Of Drugs In Dermatology
|
10/02/18
|
Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On Bryhali™* (Halobetasol Propionate) Lotion, 0.01% In The Journal Of Drugs In Dermatology
|
PDF
|
Salix Resolves Legacy SEC Investigation With No Penalty
|
09/28/18
|
Salix Resolves Legacy SEC Investigation With No Penalty
|
PDF
|
Bausch Health Releases First Annual Corporate Social Responsibility Report
|
09/27/18
|
Bausch Health Releases First Annual Corporate Social Responsibility Report
|
PDF
|
Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)
|
09/27/18
|
Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)
|
PDF
|
Bausch Health Announces Redemption Of $125 Million Aggregate Principal Amount Of Its Outstanding 7.50% Senior Notes Due 2021
|
09/26/18
|
Bausch Health Announces Redemption Of $125 Million Aggregate Principal Amount Of Its Outstanding 7.50% Senior Notes Due 2021
|
PDF
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
09/24/18
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
Bausch Health Announces Resolution Of XIFAXAN® Intellectual Property Litigation
|
09/12/18
|
Bausch Health Announces Resolution Of XIFAXAN® Intellectual Property Litigation
|
PDF
|
Bausch Health Reduces Debt By Additional $107 Million, Eliminating All Remaining Mandatory Amortization For 2018
|
09/11/18
|
Bausch Health Reduces Debt By Additional $107 Million, Eliminating All Remaining Mandatory Amortization For 2018
|
PDF
|
Salix Announces U.S. Launch of PLENVU®, the First and Only 1-Liter PEG Bowel Cleansing Preparation for Colonoscopies
|
09/11/18
|
Salix Announces U.S. Launch of PLENVU®, the First and Only 1-Liter PEG Bowel Cleansing Preparation for Colonoscopies
|
PDF
|
LUMIFY™ Redness Reliever Eye Drops Honored By The National Association of Chain Drug Stores As Product Showcase Winner
|
09/10/18
|
LUMIFY™ Redness Reliever Eye Drops Honored By The National Association of Chain Drug Stores As Product Showcase Winner
|
PDF
|
Bausch Health Companies To Participate At The Morgan Stanley Global Healthcare Conference
|
09/06/18
|
Bausch Health Companies To Participate At The Morgan Stanley Global Healthcare Conference
|
PDF
|
Bausch + Lomb Announces Publication Of Pivotal Phase 3 Data On Loteprednol Etabonate Ophthalmic Gel, 0.38% In Journal Of Cataract And Refractive Surgery
|
09/05/18
|
Bausch + Lomb Announces Publication Of Pivotal Phase 3 Data On Loteprednol Etabonate Ophthalmic Gel, 0.38% In Journal Of Cataract And Refractive Surgery
|
PDF
|
US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine) At 2018 PAINWeek Conference
|
09/04/18
|
US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine) At 2018 PAINWeek Conference
|
PDF
|
FDA Accepts Resubmission Of New Drug Application For Duobrii™1 (Halobetasol Propionate And Tazarotene) Lotion
|
08/29/18
|
FDA Accepts Resubmission Of New Drug Application For Duobrii™1 (Halobetasol Propionate And Tazarotene) Lotion
|
PDF
|
Ortho Dermatologics Receives FDA Approval For ALTRENO™ (tretinoin 0.05%) Lotion For Acne
|
08/24/18
|
Ortho Dermatologics Receives FDA Approval For ALTRENO™ (tretinoin 0.05%) Lotion For Acne
|
PDF
|
Ortho Dermatologics Resubmits U.S. New Drug Application For DUOBRII™ (halobetasol propionate and tazarotene) Lotion
|
08/15/18
|
Ortho Dermatologics Resubmits U.S. New Drug Application For DUOBRII™ (halobetasol propionate and tazarotene) Lotion
|
PDF
|
Ortho Dermatologics Announces 2018 Aspire Higher Scholarship Recipients
|
08/08/18
|
Ortho Dermatologics Announces 2018 Aspire Higher Scholarship Recipients
|
PDF
|
Bausch Health Companies Inc. Announces Second-Quarter 2018 Results
|
08/07/18
|
Bausch Health Companies Inc. Announces Second-Quarter 2018 Results
|
PDF
|
US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA™ (lofexidine) 0.18 Mg Tablets
|
08/06/18
|
US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA™ (lofexidine) 0.18 Mg Tablets
|
PDF
|
Salix Expands Microbiome Research And Discovery Through Strategic Collaboration With Cedars-Sinai Medical Center
|
08/03/18
|
Salix Expands Microbiome Research And Discovery Through Strategic Collaboration With Cedars-Sinai Medical Center
|
PDF
|
Bausch Health Companies Will Release Second-Quarter 2018 Financial Results On August 7
|
07/18/18
|
Bausch Health Companies Will Release Second-Quarter 2018 Financial Results On August 7
|
PDF
|
Bausch Health Companies Inc. Begins Trading Today as "BHC" on NYSE and TSX
|
07/16/18
|
Bausch Health Companies Inc. Begins Trading Today as "BHC" on NYSE and TSX
|
PDF
|
Bausch Health Companies Inc. completes name change
|
07/13/18
|
Bausch Health Companies Inc. completes name change
|
PDF
|
Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%
|
07/09/18
|
Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%
|
PDF
|
Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine)
|
06/26/18
|
Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine)
|
PDF
|
FDA Issues Complete Response Letter For DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion
|
06/18/18
|
FDA Issues Complete Response Letter For DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion
|
PDF
|
Bausch + Lomb Launches Soothe® Xtra Protection Preservative Free Lubricant Eye Drops
|
06/14/18
|
Bausch + Lomb Launches Soothe® Xtra Protection Preservative Free Lubricant Eye Drops
|
PDF
|
Bausch + Lomb Introduces Ocuvite® Blue Light Eye Vitamins
|
06/12/18
|
Bausch + Lomb Introduces Ocuvite® Blue Light Eye Vitamins
|
PDF
|
Valeant Announces Closing Of Amended And Restated Credit Agreement Transaction And Senior Notes Offering, As Well As Redemption Of Existing Senior Notes
|
06/01/18
|
Valeant Announces Closing Of Amended And Restated Credit Agreement Transaction And Senior Notes Offering, As Well As Redemption Of Existing Senior Notes
|
PDF
|
Salix To Highlight New Clinical Data During Digestive Disease Week
|
05/31/18
|
Salix To Highlight New Clinical Data During Digestive Disease Week
|
PDF
|
Valeant Announces Pricing Of Private Offering Of Notes
|
05/17/18
|
Valeant Announces Pricing Of Private Offering Of Notes
|
PDF
|
Valeant Announces Launch Of Private Offering Of Notes And Upsize Of Term Loans
|
05/17/18
|
Valeant Announces Launch Of Private Offering Of Notes And Upsize Of Term Loans
|
PDF
|
Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference
|
05/15/18
|
Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference
|
PDF
|
Valeant To Participate At 2018 Bank Of America Merrill Lynch Healthcare Conference
|
05/10/18
|
Valeant To Participate At 2018 Bank Of America Merrill Lynch Healthcare Conference
|
PDF
|
Valeant To Seek Refinancing of its Existing Credit Agreement
|
05/10/18
|
Valeant To Seek Refinancing of its Existing Credit Agreement
|
PDF
|
Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance
|
05/08/18
|
Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance
|
PDF
|
Valeant Will Become Bausch Health Companies Inc.
|
05/08/18
|
Valeant Will Become Bausch Health Companies Inc.
|
PDF
|
Bausch + Lomb Launches LUMIFY, The First And Only OTC Redness Relieving Eye Drop With Low-Dose Brimonidine
|
05/07/18
|
Bausch + Lomb Launches LUMIFY, The First And Only OTC Redness Relieving Eye Drop With Low-Dose Brimonidine
|
PDF
|
Salix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies
|
05/07/18
|
Salix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies
|
PDF
|
Valeant To Participate At Goldman Sachs Third Annual Leveraged Finance Conference
|
05/03/18
|
Valeant To Participate At Goldman Sachs Third Annual Leveraged Finance Conference
|
PDF
|
Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection
|
05/02/18
|
Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection
|
PDF
|
Bausch + Lomb ULTRA® Contact Lenses Receive FDA Approval for Extended Wear Indication
|
05/02/18
|
Bausch + Lomb ULTRA® Contact Lenses Receive FDA Approval for Extended Wear Indication
|
PDF
|
Valeant announces 2018 Annual Meeting Results
|
05/01/18
|
Valeant announces 2018 Annual Meeting Results
|
PDF
|
Bausch + Lomb Will Present Scientific And Clinical Research During The Association For Research In Vision And Ophthalmology Meeting
|
04/27/18
|
Bausch + Lomb Will Present Scientific And Clinical Research During The Association For Research In Vision And Ophthalmology Meeting
|
PDF
|
Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE By ONE Program
|
04/19/18
|
Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE By ONE Program
|
PDF
|
Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020
|
04/12/18
|
Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020
|
PDF
|
Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration
|
04/12/18
|
Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration
|
PDF
|
Bausch + Lomb to Showcase New Scientific Data During the Annual Meeting of the American Society of Cataract and Refractive Surgery
|
04/11/18
|
Bausch + Lomb to Showcase New Scientific Data During the Annual Meeting of the American Society of Cataract and Refractive Surgery
|
PDF
|
Valeant And One Of Its Subsidiaries Announce Expiration And Final Settlement Date For Cash Tender Offers For Senior Notes
|
04/10/18
|
Valeant And One Of Its Subsidiaries Announce Expiration And Final Settlement Date For Cash Tender Offers For Senior Notes
|
PDF
|
Ortho Dermatologics Announces Publication Of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII™ In The Journal of the American Academy of Dermatology
|
04/09/18
|
Ortho Dermatologics Announces Publication Of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII™ In The Journal of the American Academy of Dermatology
|
PDF
|
Valeant Will Release First-Quarter 2018 Financial Results On May 8
|
04/06/18
|
Valeant Will Release First-Quarter 2018 Financial Results On May 8
|
PDF
|
Salix Launches 'Let's Talk 2' IBS Awareness Campaign
|
04/03/18
|
Salix Launches 'Let's Talk 2' IBS Awareness Campaign
|
PDF
|
Valeant and One of its Subsidiaries Announce Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes
|
03/26/18
|
Valeant and One of its Subsidiaries Announce Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes
|
PDF
|
Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount
|
03/12/18
|
Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount
|
PDF
|
Valeant Announces Pricing of Private Offering of Senior Notes
|
03/12/18
|
Valeant Announces Pricing of Private Offering of Senior Notes
|
PDF
|
Valeant Announces Launch Of Private Offering Of Senior Notes
|
03/12/18
|
Valeant Announces Launch Of Private Offering Of Senior Notes
|
PDF
|
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,250,000,000 Outstanding Principal Amount
|
03/12/18
|
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,250,000,000 Outstanding Principal Amount
|
PDF
|
Valeant To Participate At The 2018 Barclays Global Healthcare Conference
|
03/08/18
|
Valeant To Participate At The 2018 Barclays Global Healthcare Conference
|
PDF
|
Valeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance
|
02/28/18
|
Valeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance
|
PDF
|
Valeant Announces Redemption Of Remaining $71 Million Aggregate Principal Amount Of Its Outstanding 7.00% Senior Unsecured Notes Due 2020
|
02/28/18
|
Valeant Announces Redemption Of Remaining $71 Million Aggregate Principal Amount Of Its Outstanding 7.00% Senior Unsecured Notes Due 2020
|
PDF
|
Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis
|
02/27/18
|
Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis
|
PDF
|
Ortho Dermatologics Presents An Analysis Of SILIQTM (Brodalumab) Injection Phase 3 Data On Disease-Related Anxiety And Depression In Patients With Moderate-To-Severe Plaque Psoriasis
|
02/16/18
|
Ortho Dermatologics Presents An Analysis Of SILIQTM (Brodalumab) Injection Phase 3 Data On Disease-Related Anxiety And Depression In Patients With Moderate-To-Severe Plaque Psoriasis
|
PDF
|
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For JEMDEL™ Plaque Psoriasis Treatment
|
02/14/18
|
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For JEMDEL™ Plaque Psoriasis Treatment
|
PDF
|
Salix provides update on FDA submission for PLENVU®*
|
02/09/18
|
Salix provides update on FDA submission for PLENVU®*
|
PDF
|
Salix provides update on FDA submission for PLENVU®*
|
02/09/18
|
Salix provides update on FDA submission for PLENVU®*
|
PDF
|
Valeant Will Release Fourth-Quarter And Full-Year 2017 Financial Results On February 28
|
02/06/18
|
Valeant Will Release Fourth-Quarter And Full-Year 2017 Financial Results On February 28
|
PDF
|
Valeant Will Reduce Debt By An Additional $200 Million
|
01/25/18
|
Valeant Will Reduce Debt By An Additional $200 Million
|
PDF
|
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form
|
01/12/18
|
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form
|
PDF
|
Valeant Provides Company Update At The 36th Annual J.P. Morgan Healthcare Conference
|
01/09/18
|
Valeant Provides Company Update At The 36th Annual J.P. Morgan Healthcare Conference
|
PDF
|
Bausch + Lomb Receives CE Mark From The European Commission For The Stellaris Elite™ Vision Enhancement System, Including The Vitesse™ Vitrectomy System
|
01/08/18
|
Bausch + Lomb Receives CE Mark From The European Commission For The Stellaris Elite™ Vision Enhancement System, Including The Vitesse™ Vitrectomy System
|
PDF
|
Valeant Pays Down $300 Million Of Senior Secured Term Loans
|
01/03/18
|
Valeant Pays Down $300 Million Of Senior Secured Term Loans
|
PDF
|
Valeant To Present At The 36th Annual J.P. Morgan Healthcare Conference
|
01/03/18
|
Valeant To Present At The 36th Annual J.P. Morgan Healthcare Conference
|
PDF
|